Approval · Notice of Compliance 26264 · 2021
ENTRESTO: Notice of Compliance 26264
Issued July 14, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26264
- Date
- July 14, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph with new pharmacokinetic (PK) and pharmacodynamic (PD) information in pediatric patients
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENTRESTO | Not yet assigned | — |
Medicinal ingredients
- VALSARTAN 26 MG per TAB
- SACUBITRIL 24 MG per TAB
- VALSARTAN 51 MG per TAB
- SACUBITRIL 49 MG per TAB
- VALSARTAN 103 MG per TAB
- SACUBITRIL 97 MG per TAB